Chemed Corp stock hits 52-week high at 558.32 USD

Chemed Corp's stock reached a new peak, trading at 558.32 USD, marking a 52-week high for the company. Currently priced at $556.66, Chemed boasts an impressive market capitalization of $7.2 billion, reflecting a 15.99% increase over the past year and demonstrating robust investor confidence. According to InvestingPro's analysis, the stock appears undervalued, positioning Chemed among the most undervalued stocks on the platform's list.

The company boasts an impressive track record, having raised its dividend for 17 consecutive years, placing it among 12+ InvestingPro Tips for deeper analysis. This upward trajectory underscores Chemed's resilience and potential for further growth in the market. Recently, Chemed Corporation reported second-quarter results that surpassed Wall Street expectations, with adjusted earnings of $6.06 per share on $673.25 million in revenue.

This success was attributed to the strong performance of its VITAS hospice unit and steady results from Roto-Rooter. Furthermore, Jefferies upgraded Chemed's stock rating from Hold to Buy, citing improved earnings stability and a potential expansion in valuation. The firm now has a price target of $620, anticipating stable earnings growth.

UBS also initiated coverage on Chemed, assigning a Buy rating and setting a price target of $650. UBS anticipates low double-digit adjusted earnings per share growth in the coming years, with 19% projected growth in 2026. These developments collectively paint a positive picture of Chemed's financial performance. This report was AI-generated with an editorial review and is intended to provide a comprehensive account of the story.